Healthcare providers are licensed to prescribe Campath® (alemtuzumab) to treat a specific kind of leukemia called B-cell chronic lymphocytic leukemia. It works by signaling the immune system to bind to a certain type of antigen in white blood cells, which causes the cancer cells to die. This drug is given via infusion in a healthcare setting.
How effective are Campath injections? In clinical trials, 83 percent of those given Campath were said to have responded to treatment (had a decrease in signs of leukemia), compared to 55 percent of people given chlorambucil (Leukeran®), another leukemia medicine. For some people (24 percent), the leukemia symptoms completely disappeared.
(Click Campath to learn more about the effectiveness of this drug, dosing guidelines, what to do in cases of overdose, and more.)
Written by/reviewed by: Kristi Monson, PharmD;Arthur Schoenstadt, MD
eMedTV serves only as an informational resource. This site does not dispense medical advice or advice of any kind.
Site users seeking medical advice about their specific situation should consult with their own physician. Click